Andrew Armstrong
Overview:
1. Predictors of sensitivity and clinical efficacy of therapies in advanced prostate cancer
2. Novel designs of clinical trials and pharmacodynamic/translational studies in prostate, kidney, bladder cancer
3. Pre-operative models for drug development of novel agents in human testing in prostate cancer
4. Novel therapies and drug development for prostate, renal, bladder, and testicular cancer
5. Design of rational combination therapies in men with metastatic hormone-refractory prostate cancer
6. PI3 kinase/mTOR inhibition in prostate cancer: mechanisms of sensitivity and resistance
7. Developing prognostic models for progression and survival in metastatic prostate cancer
8. Examining surrogate markers of mortality in metastatic prostate cancer
9. Clear cell and non-clear cell renal cell carcinoma: natural history, sensitivity to novel agents including mTOR and VEGF inhibition
2. Novel designs of clinical trials and pharmacodynamic/translational studies in prostate, kidney, bladder cancer
3. Pre-operative models for drug development of novel agents in human testing in prostate cancer
4. Novel therapies and drug development for prostate, renal, bladder, and testicular cancer
5. Design of rational combination therapies in men with metastatic hormone-refractory prostate cancer
6. PI3 kinase/mTOR inhibition in prostate cancer: mechanisms of sensitivity and resistance
7. Developing prognostic models for progression and survival in metastatic prostate cancer
8. Examining surrogate markers of mortality in metastatic prostate cancer
9. Clear cell and non-clear cell renal cell carcinoma: natural history, sensitivity to novel agents including mTOR and VEGF inhibition
Positions:
Professor of Medicine
Medicine, Medical Oncology
School of Medicine
Associate Professor in Pharmacology and Cancer Biology
Pharmacology & Cancer Biology
School of Medicine
Professor in Surgery
Surgery, Urology
School of Medicine
Member of the Duke Cancer Institute
Duke Cancer Institute
School of Medicine
Education:
B.S.E. 1996
Duke University
M.D. 2000
University of Virginia School of Medicine
M.Sc. 2008
Johns Hopkins University
Internship/Residency, General Internal Medicine
University of Pennsylvania School of Medicine
Fellowship, Division Of Oncology/Hematology
Johns Hopkins University School of Medicine
Grants:
Propel Protocol ID: D081SC00001
Administered By
Duke Cancer Institute
Role
Principal Investigator
Start Date
End Date
ProSTAR: CPI-1205
Administered By
Duke Cancer Institute
Role
Principal Investigator
Start Date
End Date
VISION PSMA-617-01
Administered By
Duke Cancer Institute
Role
Principal Investigator
Start Date
End Date
A Phase 2 Study of Nivolumab in combination with either Rucaparib, docetaxel, or enzalutamide in men with Castration-resistant metastaic prostate cancer (CheckMate 9KD: CHECKpoint pathway and nivoluMA
Administered By
Duke Cancer Institute
Role
Principal Investigator
Start Date
End Date
MK7123
Administered By
Duke Cancer Institute
Role
Principal Investigator
Start Date
End Date
Publications:
Multicenter retrospective analysis of patients with metastatic renal cell carcinoma (mRCC) and bone metastases treated with ipilimumab and nivolumab
Authors
Desai, K; Brown, LC; Wei, W; Allman, KD; Martin, A; Wood, LS; Gupta, S; Gilligan, TD; Garcia, JA; Kao, C; Kinsey, EN; Healy, P; Kephart, J; Harrison, MR; Ramalingam, S; Armstrong, AJ; George, DJ; Rini, BI; Zhang, T; Ornstein, MC
MLA Citation
Desai, Kunal, et al. “Multicenter retrospective analysis of patients with metastatic renal cell carcinoma (mRCC) and bone metastases treated with ipilimumab and nivolumab.” Journal of Clinical Oncology, vol. 38, no. 6, AMER SOC CLINICAL ONCOLOGY, 2020.
URI
https://scholars.duke.edu/individual/pub1441329
Source
wos
Published In
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Volume
38
Published Date
A multicenter retrospective study to evaluate real-world clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) and brain metastasis treated with ipilimumab and nivolumab
Authors
Brown, LC; Desai, K; Kao, C; Kinsey, EN; Healy, P; Kephart, J; Harrison, MR; Ramalingam, S; Armstrong, AJ; George, DJ; Martin, A; Allman, KD; Wood, LS; Wei, W; Garcia, JA; Gilligan, TD; Gupta, S; Rini, BI; Ornstein, MC; Zhang, T
MLA Citation
Brown, Landon Carter, et al. “A multicenter retrospective study to evaluate real-world clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) and brain metastasis treated with ipilimumab and nivolumab.” Journal of Clinical Oncology, vol. 38, no. 6, AMER SOC CLINICAL ONCOLOGY, 2020.
URI
https://scholars.duke.edu/individual/pub1441330
Source
wos
Published In
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Volume
38
Published Date
Metastatic Hormone-Sensitive Prostate Cancer: A Review of the Current Treatment Landscape.
PURPOSE: In recent years, the treatment options for metastatic hormone-sensitive prostate cancer (mHSPC) have expanded significantly. In addition to androgen deprivation therapy, the systemic treatments now include docetaxel, abiraterone, enzalutamide, and apalutamide. Radiation to the primary is also an option for select low-volume patients. METHODS: We conducted a review of the pivotal trials that have changed the practice of mHSPC. RESULTS: We describe an overview of the trials that investigated docetaxel (CHAARTED and STAMPEDE-Docetaxel), abiraterone (LATTITUDE and STAMPEDE-Abiraterone), enzalutamide (ARCHES, ENZAMET), apalutamide (TITAN), and radiation to the primary (STAMPEDE-Radiation). DISCUSSION: The treatment of mHSPC is a complex topic, and treatment choice should be individualized. Patient preferences, cost, volume of disease, and side effect profiles are important in determining which option is the best for an individual patient.
Authors
Kinsey, EN; Zhang, T; Armstrong, AJ
MLA Citation
Kinsey, Emily N., et al. “Metastatic Hormone-Sensitive Prostate Cancer: A Review of the Current Treatment Landscape.” Cancer J, vol. 26, no. 1, pp. 64–75. Pubmed, doi:10.1097/PPO.0000000000000418.
URI
https://scholars.duke.edu/individual/pub1428004
PMID
31977388
Source
pubmed
Published In
Cancer J
Volume
26
Start Page
64
End Page
75
DOI
10.1097/PPO.0000000000000418
CDK12-mutated prostate cancer (PC): Clinical outcomes to standard therapies and immune checkpoint blockade
Authors
Schweizer, MT; Gulati, R; Brown, LC; Mckay, RR; Dorff, TB; Kilari, D; Vats, P; Patel, VG; Oh, WK; Armstrong, AJ; Montgomery, RB; Alva, AS
MLA Citation
Schweizer, Michael Thomas, et al. “CDK12-mutated prostate cancer (PC): Clinical outcomes to standard therapies and immune checkpoint blockade.” Journal of Clinical Oncology, vol. 38, no. 6, AMER SOC CLINICAL ONCOLOGY, 2020.
URI
https://scholars.duke.edu/individual/pub1441331
Source
wos
Published In
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Volume
38
Published Date
A post hoc analysis of radiographic progression with nonrising prostate-specific antigen in patients with metastatic castration-resistant prostate cancer (mCRPC) in the PREVAIL study
Authors
Bryce, AH; Alumkal, JJ; Armstrong, A; Higano, CS; Iversen, P; Sternberg, CN; Rathkopf, DE; Loriot, Y; de Bono, J; Tombal, B; Abhyankar, S; Lin, P; Krivoshik, A; Phung, D; Beer, TM
MLA Citation
Bryce, A. H., et al. “A post hoc analysis of radiographic progression with nonrising prostate-specific antigen in patients with metastatic castration-resistant prostate cancer (mCRPC) in the PREVAIL study.” Annals of Oncology, vol. 27, 2016, p. vi258. Scopus, doi:10.1093/annonc/mdw372.44.
URI
https://scholars.duke.edu/individual/pub1241663
Source
scopus
Published In
Annals of Oncology
Volume
27
Published Date
Start Page
vi258
DOI
10.1093/annonc/mdw372.44
Professor of Medicine
Contact:
Duke Box 103861, Durham, NC 27710
GSRB1 Room 3006, 905 La Salle St, Durham, NC 27710